BET bromodomain inhibitor birabresib in mantle cell lymphoma: in vivo activity and identification of novel combinations to overcome adaptive resistance

BACKGROUND: The outcome of patients affected by mantle cell lymphoma (MCL) has improved in recent years, but there is still a need for novel treatment strategies for these patients. Human cancers, including MCL, present recurrent alterations in genes that encode transcription machinery proteins and...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:ESMO Open
Autori principali: Tarantelli, Chiara, Bernasconi, Elena, Gaudio, Eugenio, Cascione, Luciano, Restelli, Valentina, Arribas, Alberto Jesus, Spriano, Filippo, Rinaldi, Andrea, Mensah, Afua Adjeiwaa, Kwee, Ivo, Ponzoni, Maurilio, Zucca, Emanuele, Carrassa, Laura, Riveiro, Maria E, Rezai, Keyvan, Stathis, Anastasios, Cvitkovic, Esteban, Bertoni, Francesco
Natura: Artigo
Lingua:Inglês
Pubblicazione: BMJ Publishing Group 2018
Soggetti:
Original Research
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6173228/
https://ncbi.nlm.nih.gov/pubmed/30305939
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/esmoopen-2018-000387
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi